Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01410240 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty
A Phase 4 study, sponsored by Baxter Healthcare Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 137
- Enrollment target
NCT01410240: Completed Phase 4 study, sponsored by Baxter Healthcare Corporation.
NCT01410240 is a Phase 4 study that has completed, run by Baxter Healthcare Corporation. The registered enrollment target is 137 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01410240, a Phase 4 study, has completed, sponsored by Baxter Healthcare Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 137 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of FLOSEAL to standard of care for hemostasis in subjects undergoing total knee arthroplasty.
Interventions
- PROCEDURE Standard of Care
- DRUG FLOSEAL Hemostatic Matrix + Standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
What the finished NCT01410240 record still lists
NCT01410240 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT01410240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01410240 about?
NCT01410240 is a clinical study titled "Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty". The purpose of this study is to compare the efficacy and safety of FLOSEAL to standard of care for hemostasis in subjects undergoing total knee arthroplasty.
What is the current status of trial NCT01410240?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 137 participants. The study started on 2011-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01410240?
The interventions under investigation include: Standard of Care (PROCEDURE), FLOSEAL Hemostatic Matrix + Standard of care (DRUG).
Who is sponsoring clinical trial NCT01410240?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01410240's enrollment target sits among peer trials
137 594th of 2000 higher than 1,405 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia